Trending Tickers: Actavis plc (NYSE:ACT), AK Steel Holding Corporation (NYSE:AKS), Versar Inc. (NYSEMKT:VSR), Signal Genetics, Inc. (NASDAQ:SGNL), Allied Nevada Gold Corp. (NYSEMKT:ANV)

Actavis PLC (NYSE:ACT) agreed to pay about $66 billion for Allergan Inc., the maker of the antiwrinkle treatment Botox, in the year’s biggest pharmaceutical deal. The cash-and-stock purchase, in which Actavis will pay $219 a share, also puts an end to Valeant Pharmaceuticals International Inc.’s months-long hostile takeover fight for Allergan, a move backed by activist investor Bill Ackman. Actavis plc (NYSE:ACT) belongs to Healthcare sector. Its net profit margin is -8.10% and weekly performance is 10.66%. On last trading day company shares ended up $269.60. Actavis plc (NYSE:ACT) distance from 50-day simple moving average (SMA50) is 12.96%.

AK Steel Holding Corporation (NYSE:AKS) on Nov. 6 said the U.S. International Trade Commission (ITC) reached an affirmative (4-1) final determination that the domestic industry producing non-oriented electrical steel (NOES) is materially injured by reason of dumped and subsidized imports from six countries. AK Steel Holding Corporation (NYSE:AKS) shares decreased -0.78% in last trading session and ended the day at $6.39. AKS Gross Margin is 7.20% and its return on assets is -1.90%. AK Steel Holding Corporation (NYSE:AKS) quarterly performance is -37.48%.

Virginia-based Versar Inc. (NYSEMKT:VSR) has announced that its wholly-owned subsidiary, VersarPPS, has received an additional $800,000 contract to supply chemical splash protection suits to the United Kingdom’s Department for International Development (DFID), for use in the event of an Ebola outbreak. Versar previously announced a protection contract of $5.1 million, bringing the total contract value to nearly $6 million. On 18 November, Versar Inc. (NYSEMKT:VSR) shares remains unchanged and was closed at $2.99. VSR EPS growth in last 5 year was -16.50%. Versar Inc. (NYSEMKT:VSR) year to date (YTD) performance is -38.10%.

Signal Genetics, Inc. (NASDAQ:SGNL) said on Friday that its third quarter revenues increased 32 percent year over year. For the three months ended Sept. 30, the Carlsbad, Calif.-based cancer diagnostics firm said that revenues rose to $1.3 million from $983,589 in the year-ago quarter. “During the third quarter, we continued to execute on our business strategy by significantly growing our revenue, extending a key partnership and expanding our leadership team,” Signal President and CEO Samuel Riccitelli said in a statement. Signal Genetics, Inc. (NASDAQ:SGNL) ended the last trading day at $3.20. Company weekly volatility is calculated as 5.14% and price to cash ratio as 1.57. Signal Genetics, Inc. (NASDAQ:SGNL) showed a weekly performance of 2.89%.

Allied Nevada Gold Corp. (NYSEMKT:ANV) declared the filing on SEDAR of a National Instrument 43-101 Technical Report signifying the succeeding report for the lately declared feasibility research for the Hycroft mill development project. Recently the firm declared a loss of $62.4 million in its Q3 of 2014. Allied Nevada Gold Corp. (NYSEMKT:ANV) shares moved up 22.16% in last trading session and ended the day at $2.04. ANV Gross Margin is 13.90% and its return on assets is -5.10%. Allied Nevada Gold Corp. (NYSEMKT:ANV) quarterly performance is -41.04%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone